Phase I, randomized, double-blind, single-dose study to assess the pharmacokinetics, safety, and immunogenicity of the proposed biosimilar SCT630 and adalimumab in healthy Chinese subjects

•A randomized controlled clinical study was performed in healthy men.•We compared the PK, safety, and immunogenicity of SCT630 and adalimumab.•SCT630 and adalimumab appeared to have bioequivalent pharmacokinetics.•Treatment-emergent adverse events were observed in both groups.•SCT630 and adalimumab have similar pharmacokinetics and are safe and well tolerated.